(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 90.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Geron's revenue in 2025 is $76,994,000.On average, 5 Wall Street analysts forecast GERN's revenue for 2025 to be $146,099,516,373, with the lowest GERN revenue forecast at $133,546,129,270, and the highest GERN revenue forecast at $169,607,660,361. On average, 5 Wall Street analysts forecast GERN's revenue for 2026 to be $228,948,049,831, with the lowest GERN revenue forecast at $169,365,636,662, and the highest GERN revenue forecast at $265,984,044,761.
In 2027, GERN is forecast to generate $342,840,580,965 in revenue, with the lowest revenue forecast at $226,445,015,264 and the highest revenue forecast at $453,635,208,758.